Elevance Health Beats Estimates but Margins Drop Sharply

What happened

Elevance Health reported second-quarter 2026 adjusted earnings per share of $7.45, beating analyst expectations of $6.21. Operating revenue reached $49.8 billion, up 0.8% year-over-year, driven by higher premium yields. The company raised its full-year adjusted EPS guidance to at least $27.00, up from at least $26.75 previously.

However, Elevance's adjusted operating margin fell to 3.6%, down from 5.0% a year earlier, driven primarily by margin compression in its Health Benefits division. The company's medical loss ratio rose to 89.7% from 88.9% in the prior year. Net income declined more than 16% year-over-year to $1.5 billion.

Medical membership dropped by almost 470,000 people sequentially, ending the quarter at 44.9 million. The losses were concentrated in employer-sponsored plans, Medicaid, and ACA plans, though ACA retention performed better than expected.

Elevance announced it is exiting Washington, D.C.'s Medicaid market effective August 1, and plans to leave additional Medicaid markets over the next 12-18 months. The company covers 8.4 million Medicaid beneficiaries across more than a dozen states, generating $14.4 billion in premiums in the second quarter. Medicaid is expected to operate at a -1.75% operating margin in 2026.

The insurer also settled CMS allegations regarding Medicare Advantage reimbursements, paying more than $342 million in May. The settlement was significantly lower than the estimated exposure of $935 million to $1.5 billion.

Why it matters

The sharp decline in operating margins, despite strong headline earnings, raises concerns about sustained profitability in Elevance's core insurance business. The Health Benefits division faces ongoing pressure from lower Medicaid reimbursement rates that have not kept pace with rising medical costs, particularly in behavioral health, specialty drugs, outpatient surgeries, and emergency care.

Elevance's decision to exit underperforming Medicaid markets signals a strategic shift toward prioritizing sustainable margins over membership growth. Management is focusing on markets where the company can sell complementary Carelon health services and maintain profitability.

The company's Medicaid business generated roughly one-third of total premium revenue in the quarter but is operating at a negative 1.75% margin, creating significant drag on overall profitability. Meanwhile, Medicare Advantage repositioning and the loss of a major employer-sponsored customer contributed to membership declines.

Investors should note that reported EPS benefited from an $0.80 per-share non-operating gain, meaning underlying profitability was weaker than headline figures suggested. Despite raising guidance, Elevance's expected $27.00 adjusted EPS remains well below the $30.29 it posted in 2025.

Bigger picture

Elevance's margin pressure triggered broad selling across the health insurance sector, with shares of UnitedHealth Group falling 2.7%, Molina Healthcare dropping 9%, Centene declining 4.9%, Humana losing 1.7%, and CVS Health falling 2.3% in premarket trading. Investors feared similar challenges could affect other managed-care companies.

The health insurance industry is navigating a difficult period following surging medical spending in Medicare, Medicaid, and ACA plans over the past two years. While first-quarter 2026 results suggested margin recovery strategies were starting to work, Elevance's second-quarter performance indicated ongoing challenges.

Medicaid is facing additional turbulence from the federal government's budget legislation, which includes almost $1 trillion in Medicaid spending cuts that threaten state funding, benefits, and member retention. However, Elevance management stated that its Medicaid exits are not driven by federal policy changes but rather by lack of sustainable profitability in certain markets.

The ACA market is also under pressure from the loss of more generous subsidies, leading to higher premiums and member attrition. Elevance now expects to end 2026 with as many as 1 million ACA members, up from prior expectations of 900,000, as retention improved.

Hospital operator HCA Healthcare recently disclosed declining medical utilization, a positive signal for insurers' cost containment efforts. However, Elevance's results suggest elevated spending persists, particularly in Medicaid.

What to watch

Monitor whether Elevance's margin pressures prove company-specific or indicative of broader industry challenges when UnitedHealth Group and other peers report earnings. Watch for announcements regarding which additional Medicaid markets Elevance plans to exit over the next 12-18 months, and whether competitors follow suit.

Track Medicaid cost trends in behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization, which management identified as key pressure points. Observe whether July 1 Medicaid rate updates and future state reimbursement adjustments are sufficient to restore profitability.

Pay attention to Elevance's one-time investments in the second half of 2026 aimed at detecting medical cost trends earlier, simplifying patient experience, and expanding Carelon health services. Watch for progress toward management's goal of returning to at least 12% adjusted EPS growth in 2027 off a $26 baseline.

Monitor membership trends, particularly in ACA and employer-sponsored plans, and whether premium increases help offset volume losses. Watch for any further regulatory developments related to Medicaid spending cuts and employment-linked eligibility mandates.